NEWS
- to come and learn why our COVID-19 solution is now used in many parts of the world – from mobile drive through testing stations, to major airports, cruise ships, laboratories, oil drilling platforms and even onboard the frigates of a major European Navy fleet
- to visit us and find out why our solution is easily associated by many users as the solution for quick and accurate point-of-care molecular tests
Singapore, October 3, 2022 – Detection of Influenza A H3N2 virus
In response to the emergence of variants of influenza A H3N2 viruses, and to mitigate any potential risks that these variants may have on our assay performance, we, Credo Diagnostics Biomedical, have performed the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving Influenza A virus detection) against the sequences of eight circulating influenza A variants (seven variants belong to clade 3C.2a1b.2a.2 and one variant belongs to clade 3C.2a1b.1a) listed in the Danish published study.¹
According to our analysis, we hereby confirm that all our Influenza A detection assays, including VitaPCR™ Flu A&B assay, VitaPCR™ Flu/RSV assay, and VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) assay, are capable of detecting these eight variants correctly.
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.
Singapore, July 26, 2022 – Credo Diagnostics presents at AACC, Chicago, IL, USA, on July 26 - 28, 2022.
At the 2019 AACC in Anaheim, CA, Booth #4339, Credo Diagnostics launched our VitaPCR™ Instrument and our first VitaPCR™ Influenza A&B Assay.
After one year, our product lines include the VitaPCR™ SARS-CoV-2 Gen 2 Assay, VitaPCR™ Influenza/SARS-CoV-2 Assay, VitaPCR™ Influenza/RSV Assay, and VitaPCR™ Strep A Assay.
For AACC 2022 in Chicago, Credo Diagnostics are happy to announce our participation, and importantly, will introduce our new molecular diagnostic platform – VitaSIRO solo™, and share what we have done since the onset of COVID-19 to help countries provide VitaPCR™ machines.
“Today, it is a great honour to see our solutions accepted and requested by users worldwide. We strive to provide the best solutions to our customers continually and we will never stop innovating."
Come visit us at Booth #4456 to see for yourself.
Credo Diagnostics, “Advanced Medical Technology For All”
Booth #4456, 2022 AACC Annual Scientific Meeting & Clinical Lab Expo
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.
Singapore, July 1, 2022 - Credo Diagnostics is pleased to announce our participation at the coming 2022 AACC Annual Scientific Meeting & Clinical Lab Expo event from July 26 - 28, 2022 in Chicago, IL, USA.
The AACC Annual Scientific Meeting & Clinical Lab Expo is the world’s leading global professional gathering for clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory medicine. It will showcase the cutting-edge science and technology changing the future of laboratory medicine.
At the 2019 AACC in Anaheim, CA, Booth #4339, Credo Diagnostics launched the VitaPCR™ Instrument and the first VitaPCR™ Influenza A&B Assay.
Today, Credo Diagnostics’ product lines include the VitaPCR™ SARS-CoV-2 Gen 2 Assay, VitaPCR™ Influenza/SARS-CoV-2 Assay, VitaPCR™ Influenza/RSV Assay, and VitaPCR™ Strep A Assay.
For the coming 2022 AACC in Chicago, Credo Diagnostics are happy to announce our participation, and importantly, Credo Diagnostics will reveal the arrival of an exciting new platform and a whole series of new Assays.
“Today, it is a great honour to see our solutions accepted and requested by users around the world. We strive to continually provide the best solutions to our customers, and we will never stop innovating." said Dr. Wong Jr. Winston, Chairman, and CEO of Credo Diagnostics Biomedical.
Come visit Credo Diagnostics at Booth #4456 to see for yourself.
Credo Diagnostics, “Advanced Medical Technology For All”
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics Biomedical develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.
Singapore, May 31, 2022 – In response to the new Omicron variant (also known as B.1.1.529), we, Credo Diagnostics Biomedical Pte Ltd, have performed the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID on May 25th, 2022.
According to our analysis, we confirm that our SARS-CoV-2 RNA detection assay* can correctly detect the new Omicron strain, including B.1.1.529 BA.1, BA.2, BA.4, and BA.5.
Meanwhile. we continue to affirm that our SARS-CoV-2 RNA detection assay is still capable of detecting the following earlier variant strains correctly
Another circulating Variant of Concern (VOC):
． Delta variant: known as B.1.617.2
Previously circulating Variants of Concern (VOC):
． Alpha variant: known as B.1.1.7
． Beta variant: known as B.1.351
． Gamma variant: known as P.1
Previously circulating Variants of Interest (VOI)
． Lambda variant: known as C.37
． Mu variant: known as B.1.621
． Eta variant: known as B.1.525
． Iota variant: known as B.1.526
． Kappa variant: known as B.1.617.1
． Zeta variant: known as P.2
． Epsilon variant: known as B.1.427/B.1.429
． Indian variant: known as B.1.617.3
* The SARS-CoV-2 RNA detection assays include:
VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
VitaPCR™ SARS-CoV-2 Gen2 Assay (PCRAE0120)
VitaPCR™ SARS-CoV-2 Assay (PCRAE0114)
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.
Taiwan, April 23, 2022 – Credo Diagnostics presents at 32nd ECCMID, Lisbon, Portugal, on April 23 - 26, 2022.
ECCMID is recognized as the world’s premier Clinical Microbiology & Infectious Diseases event and brings together experts from many fields to present their latest findings, guidelines, and experiences to an audience of 14,000 visitors. This year, the congress will feature a hybrid format to facilitate an onsite and online experience for attendees, allowing for remote and face-to-face opportunities to take part in the multifaceted program.
Credo Diagnostics will showcase the VitaPCR™ instrument, our true Point-of-Care and accurate molecular diagnostic solution based on the real-time Polymerase Chain Reaction (real-time PCR) technology. At the event, we will be providing live hands-on testing and also demonstrate how VitaDataLink, our connectivity software, solves data management issues.
We invite all visitors
✓ to come and learn why our covid-19 solution is now used in many parts of the world – from mobile drive through testing stations, to major airports, cruise ships, laboratories, oil drilling platforms, and even onboard the frigates of a major European Navy fleet
✓ to visit us and find out why our solution is easily associated by many users as the solution for quick and accurate point-of-care molecular tests
We look forward to receiving all visitors to Booth No.2-19.2.
Credo Diagnostics Booth – ECCMID, 2022
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.
Singapore, March 24, 2022 - Credo Diagnostics is pleased to announce our participation at the coming 32nd ECCMID event from April 23 - 26, 2022.
ECCMID is recognized as the world’s premier Clinical Microbiology & Infectious Diseases event and brings together experts from many fields to present their latest findings, guidelines, and experiences to an audience of 14,000 visitors. This year, the congress will feature a hybrid format to facilitate an onsite and online experience for attendees, allowing for remote and face-to-face opportunities to take part in the multifaceted program.
Credo Diagnostics will showcase the VitaPCR™ instrument, our true Point-of-Care and accurate molecular diagnostic solution based on the real-time Polymerase Chain Reaction (real-time PCR) technology. At the event, we will be providing live hands-on testing and also demonstrate how VitaDataLink, our connectivity software, solves data management issues.
We invite all visitors
We look forward to receiving all visitors to our Booth No.2-19.2.
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics Biomedical develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.